PURPOSE: To obtain the titled drug preparation having selective directivity toward tumor tissue, by sealing a number of carcinostatic agent molecules in a microcarrier produced from human erythrocyte membrane ghost and bonding an immunoglobulin on the surface of the microcarrier.
CONSTITUTION: For example, human erythrocyte is suspended in an isotonic physiological buffer solution containing a carcinostatic agent and dialyzed to obtain a microcarrier containing carcinostatic agent. The microcarrier is stirred together with a specific immunoglobulin, preferably anti-AFT monoclonal antibody, anti-CEA monoclonal antibody, etc., in the presence of chromium chloride to obtain the objective preparation consisting of immunoglobulin bonded to the surface of said microcarrier. The carcinostatic agent is transported in a living body selectively according to the kind of the specific immunoglobulin bonded to the surface of the microcarrier and the microcarrier is disintegrated at the tumor site to release the contained carcinostatic agent, which is made to contact with the tumor site to exhibit its drug action.
| WO/2018/024770 | PRODUCTION OF BIOSIMILAR USTEKINUMAB IN CHO CELLS |
| WO/2017/024515 | NOVEL ANTI-PD-1 ANTIBODIES |
MIYANO NORIYOSHI
INUI YUICHIRO
MATSUDA HIROSHI
MORISE YUTAKA
KAMIMURA YATSUHIRO
SUYAMA TADAKAZU
